Non Patent Literature 5: Japanese Journal of Clinical Psychopharmacology, 2011, Vol. 14, No. 7, pp. 1123-1129

Non Patent Literature 6: Japanese Journal of Clinical Psychopharmacology, 2012, Vol. 15, No. 3, pp. 311-321

Summary

[0005a]

In one aspect, the present disclosure refers to a use of an agent comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient in the manufacture of a medicament for preventing or treating brain atrophy in a human patient with a neurodegenerative disease with brain atrophy,

wherein the medicament is to be orally administered once a day in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

Problem to be Solved by the Invention

[0006]

Drugs which prevent progress of AD by inhibiting neurodegeneration need to be developed early. An object of the present invention is to provide a drug which prevents progress of AD and a method of preventing progress of AD.

Means for Solving Problem

[0007]

In such circumstances, the present inventors have found that Compound A or a salt thereof has an effect of suppressing brain atrophy and have completed the present invention.

[0008]

The present invention provides the following.

(1) An agent for preventing or treating brain atrophy, comprising Compound A or a salt thereof as an active ingredient.

CLAIMS

[Claim 1] Use of an agent comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient in the manufacture of a medicament for preventing or treating brain atrophy in a human patient with a neurodegenerative disease with brain atrophy,

wherein the medicament is to be orally administered once a day in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

~~[Claim 2] The use according to claim 1, wherein the medicament is to be orally administered once a day in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.~~

[Claim ~~3~~2] The use according to claim 1, wherein the medicament is to be orally administered once a day in a dose of 160 mg or 320 mg in terms of 1- (3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

~~[Claim 4] The use according to any one of claims 1 to 3, wherein the medicament is for administration to a patient with a neurodegenerative disease.~~

[Claim 3~~5~~] The use according to ~~any one of~~ claim~~s~~ 1 or 2 ~~to 3~~, wherein the medicament is for administration to a patient with Alzheimer's disease, Probable Alzheimer's disease, Possible Alzheimer's disease, Preclinical Alzheimer's disease, Prodromal Alzheimer's disease, or mild cognitive impairment.

[Claim 4~~6~~] The use according to ~~any one of~~ claim~~s~~ 1 or 2 ~~to 3~~, wherein the medicament is for administration to a patient with Alzheimer's disease, or mild cognitive impairment.

[Claim 5~~7~~] The use according to ~~any one of~~ claim~~s~~ 1 or 2 ~~to 3~~, wherein the medicament is for administration to a patient with Alzheimer's disease.

[Claim 6~~8~~] The use according to ~~any one of~~ claim~~s~~ 1 or 2 ~~to 3~~, wherein the medicament is for administration to a patient with mild cognitive impairment due to Alzheimer's disease (MCI due to AD).

[Claim 7~~9~~] The use according to Claim 3~~5~~ or Claim 4~~6~~, wherein the mild cognitive impairment is due to Alzheimer’s disease (MCI due to AD).